Atea Pharmaceuticals Announces Promising Phase 2 Results for HCV Treatment

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company developing and commercialising oral antiviral treatments, has recently reported significant efficacy data from a phase 2 trial of bemnifosbuvir and ruzasvir in hepatitis C virus (HCV). The study achieved the primary objectives of safety and SVR12 – sustained virologic response at least 12 weeks after treatment. A total of 98% of the treatment-adherent patients were able to achieve an SVR12 after only eight weeks of treatment, which further proves the effectiveness of the regimen. The study still observed high SVR12 rates of 95% when treatment non-adherent patients were added, illustrating the potency and versatility of the regimen.

No severe side effects were reported, and therefore, the treatment was safe for the patient. These findings remain rather relevant given the high burden of new HCV cases that occur annually relative to the current treatments available. Jean-Pierre Sommadossi, the chief executive officer of Atea, also pointed out that such a regimen could be great and has the probability of being a best-in-class regimen since patients only have to go for P/F twice weekly, the treatment period lasts for 5 to 7 days, and the drugs in the regimen are not known to interact with other drugs. The results have enabled Atea to strategise on Phase 3 development, where interactions with the US Food and Drug Administration (FDA) will commence early next year.

In this clinical study, in non-cirrhotic patients, patients taking the treatment in the Phase 2 study had 99% SVR12, showing the efficacy of the regimen for various genotypes of the virus. This is an 88% rate of SVR12 for the cirrhotic patients, with the treatment typically going up to 12 weeks in Phase 3 for these patients. As Atea proceeds to Phase 3, there are patient-friendly modifications in terms of having a combination product with only two pills daily instead of four, thus an improvement in pill burden for patients. The detailed findings of the Phase 2 study were planned to be unveiled at a scientific congress in 2025.